JP2024062992A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024062992A5 JP2024062992A5 JP2024015399A JP2024015399A JP2024062992A5 JP 2024062992 A5 JP2024062992 A5 JP 2024062992A5 JP 2024015399 A JP2024015399 A JP 2024015399A JP 2024015399 A JP2024015399 A JP 2024015399A JP 2024062992 A5 JP2024062992 A5 JP 2024062992A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- heavy chain
- multispecific antibody
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 8
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 8
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000012636 effector Substances 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- 208000037914 B-cell disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762609759P | 2017-12-22 | 2017-12-22 | |
| US62/609,759 | 2017-12-22 | ||
| PCT/US2018/067299 WO2019126756A1 (en) | 2017-12-22 | 2018-12-21 | Heavy chain antibodies binding to cd22 |
| JP2020534858A JP7486421B2 (ja) | 2017-12-22 | 2018-12-21 | Ｃｄ２２に結合する重鎖抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534858A Division JP7486421B2 (ja) | 2017-12-22 | 2018-12-21 | Ｃｄ２２に結合する重鎖抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024062992A JP2024062992A (ja) | 2024-05-10 |
| JP2024062992A5 true JP2024062992A5 (https=) | 2024-07-24 |
Family
ID=65041936
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534858A Active JP7486421B2 (ja) | 2017-12-22 | 2018-12-21 | Ｃｄ２２に結合する重鎖抗体 |
| JP2024015399A Pending JP2024062992A (ja) | 2017-12-22 | 2024-02-05 | Ｃｄ２２に結合する重鎖抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534858A Active JP7486421B2 (ja) | 2017-12-22 | 2018-12-21 | Ｃｄ２２に結合する重鎖抗体 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11873336B2 (https=) |
| EP (1) | EP3728319A1 (https=) |
| JP (2) | JP7486421B2 (https=) |
| KR (2) | KR102823263B1 (https=) |
| CN (1) | CN111683966B (https=) |
| AU (1) | AU2018392088A1 (https=) |
| BR (1) | BR112020012554A2 (https=) |
| CA (1) | CA3086665A1 (https=) |
| CL (3) | CL2020001703A1 (https=) |
| CO (1) | CO2020008925A2 (https=) |
| CR (1) | CR20200322A (https=) |
| EA (1) | EA202091557A1 (https=) |
| EC (1) | ECSP20042489A (https=) |
| IL (1) | IL275498B1 (https=) |
| JO (1) | JOP20200157B1 (https=) |
| MX (1) | MX2020006494A (https=) |
| MY (1) | MY204744A (https=) |
| NI (1) | NI202000050A (https=) |
| PE (1) | PE20201171A1 (https=) |
| PH (1) | PH12020550964A1 (https=) |
| SA (1) | SA520412283B1 (https=) |
| SG (1) | SG11202005880XA (https=) |
| UA (1) | UA128757C2 (https=) |
| WO (1) | WO2019126756A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CA3171906A1 (en) | 2020-03-16 | 2021-09-23 | University Of Southern California | Novel antigen binding domains and synthetic antigen receptors incorporating the same |
| KR20210143097A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
| CN116323948A (zh) * | 2020-07-16 | 2023-06-23 | 南京传奇生物科技有限公司 | Cd22结合分子及其用途 |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| EP1585768A2 (en) | 2003-01-23 | 2005-10-19 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| KR101151957B1 (ko) | 2004-07-22 | 2012-06-01 | 로저 킹돈 크레이그 | 결합 분자 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| PL2602323T3 (pl) | 2007-06-01 | 2018-06-29 | Open Monoclonal Technology, Inc. | Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| CA2734330A1 (en) | 2008-09-19 | 2010-03-25 | Medimmune, Llc | Antibodies against sonic hedgehog homolog and uses thereof |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| MX341884B (es) | 2009-03-10 | 2016-09-07 | Biogen Ma Inc | Anticuerpos anti-antigeno de maduracion de celulas b (bcma). |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP3974453A3 (en) | 2010-11-16 | 2022-08-03 | Amgen Inc. | Agents and methods for treating diseases that correlate with bcma expression |
| EP2683735A1 (en) | 2011-03-10 | 2014-01-15 | HCO Antibody, Inc. | Bispecific three-chain antibody-like molecules |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| MX361533B (es) | 2012-04-26 | 2018-12-07 | Bioatla Llc | Anticuerpos anti-cd22. |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| PT2931030T (pt) | 2012-12-14 | 2020-08-03 | Open Monoclonal Tech Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res Munich Gmbh | Moléculas de unión para bcma y cd3 |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| DK3221357T3 (da) | 2014-11-20 | 2020-08-10 | Hoffmann La Roche | Fælles letkæder og fremgangsmåder til anvendelse |
| EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| CN104710528B (zh) | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| KR20250175345A (ko) | 2016-06-21 | 2025-12-16 | 테네오바이오, 인코포레이티드 | Cd3 결합 항체 |
| IL322083A (en) * | 2016-08-24 | 2025-09-01 | Teneobio Inc | Non-human transgenic animals that produce modified heavy chain antibodies only |
| PE20241349A1 (es) | 2016-09-14 | 2024-07-03 | Teneobio Inc | Anticuerpos de union a cd3 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| CN110945026B (zh) | 2017-06-20 | 2024-03-19 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| ES2928296T3 (es) | 2017-06-30 | 2022-11-16 | Us Health | Receptores de antígenos quiméricos anti-antígenos de maduración de linfocitos B con dominios humanos |
| EP3681908A1 (en) | 2017-09-13 | 2020-07-22 | Teneobio, Inc. | Heavy chain antibodies binding to ectoenzymes |
| CN111683966B (zh) | 2017-12-22 | 2023-07-11 | 特尼奥生物股份有限公司 | 与cd22结合的重链抗体 |
| JP2021508479A (ja) | 2017-12-27 | 2021-03-11 | テネオバイオ， インコーポレイテッド | ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン |
| BR112020024074A2 (pt) | 2018-07-20 | 2021-02-17 | Teneobio, Inc. | anticorpos de cadeia pesada com ligação a cd19 |
| SG11202102713TA (en) | 2018-09-21 | 2021-04-29 | Teneobio Inc | Methods for purifying heterodimeric, multispecific antibodies |
| KR20210086651A (ko) | 2018-10-26 | 2021-07-08 | 테네오바이오, 인코포레이티드 | Cd38에 결합하는 중쇄 항체 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
| CN115023441A (zh) | 2019-12-18 | 2022-09-06 | 特诺福尔股份有限公司 | 与cd38结合的重链抗体 |
| TW202330622A (zh) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| CN115803057A (zh) | 2020-04-29 | 2023-03-14 | 特纳奥尼公司 | 治疗多发性骨髓瘤的方法 |
| CN116472049A (zh) | 2020-06-30 | 2023-07-21 | 特尼奥生物股份有限公司 | 与bcma结合的多特异性抗体 |
| TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
| KR20230148828A (ko) | 2021-02-25 | 2023-10-25 | 테네오바이오, 인코포레이티드 | 항-psma 항체 및 car-t 구조 |
| US20240182597A1 (en) | 2021-02-26 | 2024-06-06 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| KR20230166090A (ko) | 2021-04-06 | 2023-12-06 | 테네오바이오, 인코포레이티드 | 항-cd19 항체 및 car-t 구조체 |
| CN117337303A (zh) | 2021-04-16 | 2024-01-02 | 特尼奥生物股份有限公司 | 抗cd20抗体及car-t结构 |
| WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
| WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
-
2018
- 2018-12-21 CN CN201880083056.4A patent/CN111683966B/zh active Active
- 2018-12-21 KR KR1020207021048A patent/KR102823263B1/ko active Active
- 2018-12-21 WO PCT/US2018/067299 patent/WO2019126756A1/en not_active Ceased
- 2018-12-21 AU AU2018392088A patent/AU2018392088A1/en not_active Abandoned
- 2018-12-21 SG SG11202005880XA patent/SG11202005880XA/en unknown
- 2018-12-21 JP JP2020534858A patent/JP7486421B2/ja active Active
- 2018-12-21 CR CR20200322A patent/CR20200322A/es unknown
- 2018-12-21 US US16/956,502 patent/US11873336B2/en active Active
- 2018-12-21 BR BR112020012554-7A patent/BR112020012554A2/pt active Search and Examination
- 2018-12-21 MX MX2020006494A patent/MX2020006494A/es unknown
- 2018-12-21 CA CA3086665A patent/CA3086665A1/en active Pending
- 2018-12-21 MY MYPI2020003176A patent/MY204744A/en unknown
- 2018-12-21 UA UAA202004621A patent/UA128757C2/uk unknown
- 2018-12-21 EP EP18836782.5A patent/EP3728319A1/en active Pending
- 2018-12-21 EA EA202091557A patent/EA202091557A1/ru unknown
- 2018-12-21 KR KR1020257020109A patent/KR20250093583A/ko active Pending
- 2018-12-21 PE PE2020000809A patent/PE20201171A1/es unknown
-
2020
- 2020-06-18 IL IL275498A patent/IL275498B1/en unknown
- 2020-06-20 SA SA520412283A patent/SA520412283B1/ar unknown
- 2020-06-20 CL CL2020001703A patent/CL2020001703A1/es unknown
- 2020-06-21 JO JOJO/P/2020/0157A patent/JOP20200157B1/ar active
- 2020-06-22 NI NI202000050A patent/NI202000050A/es unknown
- 2020-06-22 PH PH12020550964A patent/PH12020550964A1/en unknown
- 2020-07-21 CO CONC2020/0008925A patent/CO2020008925A2/es unknown
- 2020-07-22 EC ECSENADI202042489A patent/ECSP20042489A/es unknown
-
2022
- 2022-08-18 CL CL2022002247A patent/CL2022002247A1/es unknown
-
2023
- 2023-12-07 US US18/532,880 patent/US20240117046A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015399A patent/JP2024062992A/ja active Pending
- 2024-08-01 CL CL2024002319A patent/CL2024002319A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024062992A5 (https=) | ||
| JP2023526774A5 (https=) | ||
| JP2021530236A5 (https=) | ||
| JP2022537931A5 (https=) | ||
| JP2020023523A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| JP2022545196A5 (https=) | ||
| JP2022061993A5 (https=) | ||
| JP2020184996A5 (https=) | ||
| DE69232968T2 (de) | CDR ausgetauschte humanisierte chimäre T-Zellenantikörper. | |
| FI3823990T3 (fi) | Cd19:ään sitoutuvia raskasketjun vasta-aineita | |
| JP2022512653A5 (https=) | ||
| JP2020524506A5 (https=) | ||
| JP2020528768A5 (https=) | ||
| JP2022501428A5 (https=) | ||
| JP2021527431A5 (https=) | ||
| JP2023106433A5 (https=) | ||
| JP2023537958A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| JP2021524478A5 (https=) | ||
| RU2010100638A (ru) | Композиции и способы лечения, направленные против cd20 | |
| JP2019522961A5 (https=) | ||
| JP2023536651A5 (https=) | ||
| RU2004121673A (ru) | Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей | |
| JP2023508674A5 (https=) |